- Home
- GRI vs INM Comparison
GRI vs INM Comparison
Compare GRI & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRI
- INM
- Stock Information
- Founded
- GRI 2018
- INM 1981
- Country
- GRI United States
- INM Canada
- Employees
- GRI N/A
- INM N/A
- Industry
- GRI Biotechnology: Pharmaceutical Preparations
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- GRI Health Care
- INM Health Care
- Exchange
- GRI Nasdaq
- INM Nasdaq
- Market Cap
- GRI 4.3M
- INM 4.1M
- IPO Year
- GRI N/A
- INM N/A
- Fundamental
- Price
- GRI $1.64
- INM $1.59
- Analyst Decision
- GRI Strong Buy
- INM
- Analyst Count
- GRI 2
- INM 0
- Target Price
- GRI $22.50
- INM N/A
- AVG Volume (30 Days)
- GRI 175.4K
- INM 74.5K
- Earning Date
- GRI 11-14-2025
- INM 11-13-2025
- Dividend Yield
- GRI N/A
- INM N/A
- EPS Growth
- GRI N/A
- INM N/A
- EPS
- GRI N/A
- INM N/A
- Revenue
- GRI N/A
- INM $4,942,633.00
- Revenue This Year
- GRI N/A
- INM N/A
- Revenue Next Year
- GRI N/A
- INM N/A
- P/E Ratio
- GRI N/A
- INM N/A
- Revenue Growth
- GRI N/A
- INM 7.50
- 52 Week Low
- GRI $1.10
- INM $1.67
- 52 Week High
- GRI $17.51
- INM $8.27
- Technical
- Relative Strength Index (RSI)
- GRI 41.46
- INM 23.11
- Support Level
- GRI $1.60
- INM $1.67
- Resistance Level
- GRI $1.79
- INM $1.92
- Average True Range (ATR)
- GRI 0.17
- INM 0.09
- MACD
- GRI -0.04
- INM -0.04
- Stochastic Oscillator
- GRI 7.25
- INM 4.94
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.